"Deciphering and targeting mechanisms involved in resistance to anti-angiogenic therapy is critical to realizing the full potential of this promising cancer therapy," says Dai Fukumura, MD ...

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy ...

Further gains have been made by combining TKIs with chemotherapy, anti-angiogenic therapy such as bevacizumab or ramucirumab, and bispecific antibody therapy such as amivantamab. A study in the ...

Conventional anti-angiogenic cancer therapy in which a growth factor is eliminated may aggravate tumor metastasis, becase. Because of this, there has in recent years been a greater focus on anti ...

Since tumor angiogenic pathways are intricately associated ... AADs may not necessarily be more effective in cancer therapy than anti-VEGF single-target drugs." Finally, the researchers recommend ...

Safety in the use of granulocyte-colony stimulating factor during concurrent chemotherapy and thoracic radiotherapy in patients with small-cell lung cancer: A meta-analysis. This is an ASCO Meeting ...

Therefore, intravitreal anti-VEGF therapy is currently the primary therapy for neovascular AMD. Currently, the most common therapeutic agents are ranibizumab, bevacizumab and pegaptanib which ...

Intravitreal injections with anti-VEGF biological treatments (anti-angiogenic therapies that target VEGF) are first-line therapy for treating and stabilizing exudative neovascular AMD (nAMD).

Right now, the best way to do that is with anti-angiogenic therapy. This can slow or stop vision loss from abnormal blood vessel growth, even improving eyesight for some people. During treatment ...

"Deciphering and targeting mechanisms involved in resistance to anti-angiogenic therapy is critical to realizing the full potential of this promising cancer therapy," says Dai Fukumura, MD ...